Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Regeneron Pharmaceuticals (REGN) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Regeneron Pharmaceuticals is a member of the Medical sector. This group includes 837 individual stocks and currently holds a Zacks Sector Rank of #3. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. REGN is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for REGN's full-year earnings has moved 2.89% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the latest available data, REGN has gained about 9.37% so far this year. Meanwhile, stocks in the Medical group have gained about 5.19% on average. This means that Regeneron Pharmaceuticals is outperforming the sector as a whole this year.
Looking more specifically, REGN belongs to the Medical - Biomedical and Genetics industry, a group that includes 345 individual stocks and currently sits at #69 in the Zacks Industry Rank. On average, this group has gained an average of 8.94% so far this year, meaning that REGN is performing better in terms of year-to-date returns.
REGN will likely be looking to continue its solid performance, so investors interested in Medical stocks should continue to pay close attention to the company.
Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report
Original post
Zacks Investment Research